TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91913

Peptide_Name

TsAP-S2

Activity

Antibacterial Anticancer Antifungal Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb HemoPI Hemolytic2 PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 17-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

FLGMIPKLIKKLIKAFK-NH2

FASTA

>TPDB91913|Antibacterial;Anticancer;Antifungal;Hemolysis;Toxicity|length=17
FLGMIPKLIKKLIKAFK-NH2

Formula C99H170N22O18S1

Absent Amino Acids RNDCEQHSTWYV

Common Amino Acids K

Mass 1988.64

PI 11.12

Basic Residues 5

Acidic Residues 0

Hydrophobic Residues 10

Net Charge +5

Boman Index 0.14

Hydrophobicity 0.747

Aliphatic Index 143.53

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 0

number

1

A

0

R

0

N

0

D

0

C

0

E

0

Q

1

G

0

H

3

I

3

L

5

K

1

M

2

F

1

P

0

S

0

T

0

W

0

Y

0

V

Amino Acid Distribution

A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 3 L: 3 K: 5 M: 1 F: 2 P: 1 S: 0 T: 0 W: 0 Y: 0 V: 0

Length

17

Formula

C99H170N22O18S1

Mass

1988.64

PI

11.12

Net Charge

+5

Boman Index

0.14

Hydrophobicity

0.747

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Derivative of TsAP-1, Brazilian yellow scorpion venom peptide

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 0.83 µM

Detail Source Activity Anticancer

Activity Measurement 0.83 µM

Target

Cancer Type Lung Cancer

Cell Line HI-57

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 1.6 µM

Detail Source Activity Anticancer

Activity Measurement 1.6 µM

Target

Cancer Type Lung Cancer

Cell Line H-838

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 1.8 µM

Detail Source Activity Anticancer

Activity Measurement 1.8 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 1.6 µM

Detail Source Activity Anticancer

Activity Measurement 1.6 µM

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 2.0 µM

Detail Source Activity Anticancer

Activity Measurement 2.0 µM

Target

Cancer Type Brain Tumor

Cell Line U251-MG

Tissue Affected Brain

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013